Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib + azacitidine in accelerated phase or myeloid blast crisis CML
2024-516048-24-00Phase 2Authorised
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib and azacitidine in chronic myeloid leukemia (CML) and chronic myelogenous leukemia (CML), sponsored by Centre Hospitalier de Versailles. Primary endpoint: Overall survival at 2 years. Planned start Jun 2019; status: authorised.
02
Drugs
ponatinibazacitidine
03
Conditions
chronic myeloid leukemia (CML)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-516048-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516048-24-00.